Söderquist Kruth Sofia, Persad Emma, Rakow Alexander
Department of Women's and Children's Health, Karolinska Institutet, 17177 Stockholm, Sweden.
Women's Health and Allied Health Professional Theme, Karolinska University Hospital, 17176 Stockholm, Sweden.
Nutrients. 2025 Apr 1;17(7):1228. doi: 10.3390/nu17071228.
BACKGROUND/OBJECTIVES: Probiotic supplementation has been actively investigated in preterm populations to reduce the risk of necrotizing enterocolitis (NEC) and late-onset sepsis. Despite this, few studies have focused on clinically relevant feeding tolerance and growth outcomes, and there is an alarming lack of evidence surrounding extremely preterm infants (defined as birth before 28 weeks gestational age), those most at risk of severe comorbidities. We aimed to investigate whether probiotics improve feeding tolerance, neonatal growth and neonatal morbidity among extremely preterm infants.
A literature search was conducted in Medline, Embase, Cochrane CENTRAL, Web of Science, and clinicaltrials.gov for ongoing trials. We included extremely preterm infants from randomized controlled trials and non-randomized trials with a concurrent control group. Two authors independently performed screening, data extraction and risk of bias assessment using the Risk of Bias 2 tool from Cochrane. The certainty of the evidence was assessed using GRADE.
Eleven RCTs and three non-randomized studies with a concurrent control group were included, analyzing a total of 14,888 extremely preterm infants. Meta-analyses revealed lower mean days to full enteral feeds (mean difference 1.1 days lower; 95% CI, 7.83 lower to 5.56 higher) and lower duration of parenteral nutrition (mean difference 2.4 days lower; 95% CI, 7.44 lower to 2.58 higher) in infants treated with probiotics; however, this was not statistically significant. There was a significant reduction in NEC (RR; 0.80, 95% CI; 0.68, 0.93) and all-cause mortality (RR; 0.56, 95% CI; 0.33, 0.93) in the probiotic group. All outcomes were graded at low or very low certainty of evidence.
The findings indicate a trend towards a potential beneficial effect of probiotic supplementation in reducing feeding intolerance and a notable reduction of risk of NEC and all-cause mortality in infants receiving probiotics. Future RCTs will focus on feeding intolerance, and growth outcomes are warranted.
背景/目的:已积极研究在早产人群中补充益生菌以降低坏死性小肠结肠炎(NEC)和晚发性败血症的风险。尽管如此,很少有研究关注临床相关的喂养耐受性和生长结局,而且令人担忧的是,关于极早产儿(定义为胎龄小于28周出生)这一严重合并症风险最高的群体,几乎没有相关证据。我们旨在研究益生菌是否能改善极早产儿的喂养耐受性、新生儿生长及新生儿发病率。
在Medline、Embase、Cochrane CENTRAL、Web of Science和clinicaltrials.gov中检索正在进行的试验。我们纳入来自随机对照试验和有同期对照组的非随机试验中的极早产儿。两位作者使用Cochrane的偏倚风险2工具独立进行筛选、数据提取和偏倚风险评估。使用GRADE评估证据的确定性。
纳入了11项随机对照试验和3项有同期对照组的非随机研究,共分析了14,888例极早产儿。荟萃分析显示,接受益生菌治疗的婴儿达到完全经口喂养的平均天数较少(平均差低1.1天;95%置信区间,低7.83至高5.56),肠外营养持续时间较短(平均差低2.4天;95%置信区间,低7.44至高2.58);然而,这在统计学上并不显著。益生菌组的NEC(风险比;0.80,95%置信区间;0.68,0.93)和全因死亡率(风险比;0.56,95%置信区间;0.33,0.93)显著降低。所有结局的证据确定性等级为低或非常低。
研究结果表明,补充益生菌在降低喂养不耐受方面有潜在有益作用的趋势,且接受益生菌的婴儿NEC风险和全因死亡率显著降低。未来的随机对照试验将聚焦于喂养不耐受,生长结局也值得关注。